3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform3643companies in the directory 1104ISIN verified against the check digit 7exchanges 14sectors No real-time quotes — a reference work, not a trading platform
DE · EN Newsletter
Biotech & Pharma Symbolbild · KI-generiert
Biotech & Pharma JANX

Janux Therapeutics, Inc.

JANX NASDAQ Biotech & Pharma

Stock factsheet

TickerJANX
ExchangeNASDAQ
ISIN
WKN
SectorBiotech & Pharma
Size class Small Cap
Market capitalisation 925 Mio. USD As of 2026-08-03

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.

Company profile

Janux Therapeutics is a biopharmaceutical company developing tumour-activated T cell engagers (TRACTr) and tumour-activated immune cell engagers. The platform technology aims to enable immunotherapies with improved tumour specificity and reduced systemic toxicity. The company is in clinical development with a focus on oncology.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Share price

Price data from TradingView, possibly delayed. Not investment advice.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

CompanyTickerExchangeMarket cap
Janux Therapeutics, Inc.JANX NASDAQ925 Mio. USD
Odyssey Therapeutics, Inc. ODTXNASDAQ 909 Mio. USD
Replimune Group, Inc. REPLNASDAQ 941 Mio. USD
Adlai Nortye Ltd. ANLNASDAQ 947 Mio. USD
InMode Ltd. INMDNASDAQ 959 Mio. USD
Avalo Therapeutics, Inc. AVTXNASDAQ 965 Mio. USD
Amphastar Pharmaceuticals, Inc. AMPHNASDAQ 879 Mio. USD

Investor Relations

Annual reports Not recorded yet
Investor presentation Not recorded yet
Analyst coverage Not recorded yet

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.